Global MicroRNA Market (By Application and End Use) – Prospective Landscape, Size, Share, Growth, Opportunities and Industry Forecast 2018 – 2025

Published DateReport CodeNo. of PagesReport Format
Sept – 2019AMR-2008110PDF / Excel

SelectLicense Type

Clinical Trials to bolster the overall growth of the global MicroRNA market

Clinical studies have been positive in initial phasing for several miRNAs as biomarkers and are also under Phase II. The key role played by these RNA molecules in gene expression regulation is to encourage investments in research activities to identify miRNAs involved in the formation of the tumor and its inhibition as an approach to cancer cell growth. For example, microRNA expression is associated in triple-negative breast cancer with the transition epithelial-mesenchymal, immune system, and BRCA mutations, androgen receptor expressions, and cancer cell properties.

The market is expected to exponentially increase with further developments in genomic technologies and computer approaches. Varying phases of clinical trials include a variety of microRNA therapeutic products which can potentially indicate Hepatitis C virus, vascular disease, peripheral artery disease, cardiometabolic disease and various types of cancer. Miravirsen, for example, is the first therapeutic miRNA to enter the market. The drug is in the USA, Slovakia, Romania, Poland, Germany and the Netherlands for Phase II clinical trials. In preclinical trials using these molecules, high potential demonstrated by therapeutics is anticipated to promote investment in R&D in years to come.

Cancer segment to dominate the global microRNA market in terms of application

As such RNAs are ideal applicants as noninvasive biomarkers the cancer segment has dominated the miRNA market in revenue. It is an ideal marker for the sectioning and presence by microRNAs from cells in biofluids. These molecules are additionally classified by their ability to detect types of cancer at different nodes. In the detection of breast and prostate cancer for example, miR-27b, let-7i, and miR-181b.

In different conditions of health, research instruments are used to detect, quantify and analyze miRNAs in function. Increases researchers ‘ interest in these molecules to understand the cause and mechanism of complicated metabolic and neurological disease, such as cancer, Parkinson disease and Alzheimer’s disease, identifies the significant role of molecules in translational and transcriptional Gen expression.

Strong technical support led the North America region to dominate the global market

Due to strong technical support and enhanced research infrastructure in proteomics, genomics, modern diagnostics research as well as oncology, North America is expected to dominate this market over the forecast period. The fund approval, through the European Union, is expected to contribute to market growth in Europe for initiatives such as the EpimiRNA consortium.

In addition, rapid progress is expected to foster Asia Pacific growth in genomic studies and increasing use of advanced technologies. The development of products, comprising sets and packaging, is supplemented in the region by local players in China and Japan, majorly TaKaRa Bio. Due to reproducibility and reliability issues, the design, approval and launch of products for hospital and clinical use are faced with various challenges. The complexity and low stability of miRNAs further increase the development difficulties. The spiraling demand for precision medicine and early diagnostic tests combined with the capacity for these molecules to meet this demand has, however, encouraged the search for new approaches and strategies.

Major players profiled in the global market report include Agilent Technologies; Thermofisher Scientific (Life Technologies); QIAGEN (Exiqon); Merck KGaA;  as well as NanoString Technologies, Inc. among others.

MicroRNA is a small RNA non coding which plays a major role in the use of plants and animals in degradation or repression of certain mRNAs. The growth of the market will be driven by an increasing number of biotechnology and pharmaceutical companies engaged in R & D activities, such as molecular diagnoses and therapeutics. A great deal of opportunities are anticipated in the near future to further expand fuel in virology, cardiovascular, endocrinology, genetic diseases and plant science. Recent innovations and various applications are expected to contribute over the forecast period to market growth for microRNA. The technology is used for the diagnosis and treatment of cancer as a biomarker. More investments in R&D initiatives are also expected to fuelled demand for new diagnostic tests and therapeutics. Increased RNAi therapy target selectivity and specificity, along with the adoption of models for virtual drug development, enable enterprises to minimize research and production costs.

It is expected that the shift from platform technologies to applications will well bode for market expansion. The development of drugs or biologics by virtual platforms for medication development offers important advantages over traditional models, such as reducing risks and overhead costs linked to conventional technologies. MirNAs play an important role in different biological processes, such as developmental time-control, cell proliferation, apoptosis, maintenance of stem cells, differentiation, pathways to signaling and pathogenesis, for example carcinogenesis. This factor is expected to increase market growth during the forecast period. The provision of large-scale public and private funding is one of the main factors contributing to market growth. Government investment and growing developments in technology are expected to drive further growth. It is hoped that a high disease prevalence will promote R&D in different disease classes for pharmaceutical and biotechnological companies. Increasing cardiovascular and cancer occurrences are expected to lead to a steady market rate. In 2012, around 14 million cases of cancer were recorded, according to the WHO, and in future years the number is expected to rise at an alarming rate. On the other hand, the main constraints on the global market are expected to be stringent regulations and high investment costs. High costs for the detection of miRNA and extensive and time-consuming test methods, therefore increase the overall value of the research. High failure rates and the lack of qualified professionals with excellent experience in the industry could hamper the growth of the market. Increasing cooperation and fusions between biotechnology companies and government research agencies will, however, have a positive impact on market growth.

The global microRNA market can be segmented on the basis of application, end user and geography. On the basis of application, the global microRNA market is classified into clinical diagnostics and research. Considering end user, the global microRNA market can be bifurcated into research and academic institutes, contract research organizations, biopharmaceutical companies and diagnostic centers. Based on geography, the global microRNA market is bifurcated into North America, Latin America, Europe, Middle East & Africa and Asia-Pacific.

Some of the major players operating in the global microRNA market include Affymetrix; Alnylam Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Santaris Pharma; Biogen Idec, Inc., Exiqon; Pfizer Inc., CBC Biomarker Center GmbH, Eli Lilly and Co., F. Hoffman-La Roche, GlaxoSmithKline, Novartis AG and Merck & Co. among others.

Chapter 1. Executive Summary

Chapter 2. Market Introduction

Chapter 3. Global MicroRNA Market – Analysis and Revenue Forecast 2018-2025 – Key Industry Dynamics

  • 3.1. Key Market Drivers
  • 3.2. Key Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Future Trends
  • 3.5. Impact Analysis of Drivers and Restraints

Chapter 4. Global MicroRNA Market – Analysis and Revenue Forecast 2018-2025

Chapter 5. Global MicroRNA Market – Analysis and Revenue Forecast 2018-2025 – By Application

  • 5.1. Clinical Diagnostics
  • 5.2. Research

Chapter 6. Global MicroRNA Market – Analysis and Revenue Forecast 2018-2025 – By End Use

  • 6.1. Research and academic institutes
  • 6.2. Contract research organizations
  • 6.3. Biopharmaceutical companies
  • 6.4. Diagnostic centers

Chapter 7. Global MicroRNA Market – Analysis and Revenue Forecast 2018-2025 – By Region

  • 7.1. North America
  • 7.2. Europe
  • 7.3. Asia-Pacific
  • 7.4. Latin America
  • 7.5. Middle East & Africa

Chapter 8. North America MicroRNA Market – Analysis and Revenue Forecast 2018-2025

  • 8.1. North America MicroRNA Market – By Application
    • 8.1.1. Clinical Diagnostics
    • 8.1.2. Research
  • 8.2. North America MicroRNA Market – By End Use
    • 8.2.1. Research and academic institutes
    • 8.2.2. Contract research organizations
    • 8.2.3. Biopharmaceutical companies
    • 8.2.4. Diagnostic centers
  • 8.3. North America MicroRNA Market – By Country
    • 8.3.1. U.S.
    • 8.3.2. Canada

Chapter 9. Europe MicroRNA Market – Analysis and Revenue Forecast 2018-2025

  • 9.1. Europe MicroRNA Market – By Application
    • 9.1.1. Clinical Diagnostics
    • 9.1.2. Research
  • 9.2. Europe MicroRNA Market – By End Use
    • 9.2.1. Research and academic institutes
    • 9.2.2. Contract research organizations
    • 9.2.3. Biopharmaceutical companies
    • 9.2.4. Diagnostic centers
  • 9.3. Europe MicroRNA Market – By Country
    • 9.3.1. Germany
    • 9.3.2. France
    • 9.3.3. UK
    • 9.3.4. Spain
    • 9.3.5. Italy
    • 9.3.6. Rest of Europe

Chapter 10. Asia-Pacific MicroRNA Market – Analysis and Revenue Forecast 2018-2025

  • 10.1. Asia-Pacific MicroRNA Market – By Application
    • 10.1.1. Clinical Diagnostics
    • 10.1.2. Research
  • 10.2. Asia-Pacific MicroRNA Market – By End Use
    • 10.2.1. Research and academic institutes
    • 10.2.2. Contract research organizations
    • 10.2.3. Biopharmaceutical companies
    • 10.2.4. Diagnostic centers
  • 10.3. Asia-Pacific MicroRNA Market – By Country
    • 10.3.1. China
    • 10.3.2. India
    • 10.3.3. Japan
    • 10.3.4. South Korea
    • 10.3.5. Rest of Asia-Pacific

Chapter 11. Latin America MicroRNA Market – Analysis and Revenue Forecast 2018-2025

  • 11.1. Latin America MicroRNA Market – By Application
    • 11.1.1. Clinical Diagnostics
    • 11.1.2. Research
  • 11.2. Latin America MicroRNA Market – By End Use
    • 11.2.1. Research and academic institutes
    • 11.2.2. Contract research organizations
    • 11.2.3. Biopharmaceutical companies
    • 11.2.4. Diagnostic centers
  • 11.3. Latin America MicroRNA Market – By Country
    • 11.3.1. Brazil
    • 11.3.2. Mexico
    • 11.3.3. Rest of Latin America

Chapter 12. Middle East & Africa MicroRNA Market – Analysis and Revenue Forecast 2018-2025

  • 12.1. MEA MicroRNA Market – By Application
    • 12.1.1. Clinical Diagnostics
    • 12.1.2. Research
  • 12.2. MEA MicroRNA Market – By End Use
    • 12.2.1. Research and academic institutes
    • 12.2.2. Contract research organizations
    • 12.2.3. Biopharmaceutical companies
    • 12.2.4. Diagnostic centers
  • 12.3. Middle East & Africa MicroRNA Market – By Country
    • 12.3.1. UAE
    • 12.3.2. Saudi Arabia
    • 12.3.3. Turkey
    • 12.3.4. Rest of Middle East & Africa

Chapter 13. Competitive Analysis

  • 13.1.1. Competition Dashboard
  • 13.1.2. Company Profiles
    • 13.1.2.1. Biogen Idec Inc.
    • 13.1.2.2. Pfizer Inc.
    • 13.1.2.3. Novartis AG
    • 13.1.2.4. Affymetrix
    • 13.1.2.5. Alnylam Pharmaceuticals
    • 13.1.2.6. AstraZeneca Pharmaceuticals LP
    • 13.1.2.7. Santaris Pharma
    • 13.1.2.8. CBC Biomarker Center GmbH
    • 13.1.2.9. Eli Lilly and Co.
    • 13.1.2.10. F. Hoffman-La Roche
    • 13.1.2.11. GlaxoSmithKline
    • 13.1.2.12. Merck & Co.
Report Synopsis

Clinical Trials to bolster the overall growth of the global MicroRNA market

Clinical studies have been positive in initial phasing for several miRNAs as biomarkers and are also under Phase II. The key role played by these RNA molecules in gene expression regulation is to encourage investments in research activities to identify miRNAs involved in the formation of the tumor and its inhibition as an approach to cancer cell growth. For example, microRNA expression is associated in triple-negative breast cancer with the transition epithelial-mesenchymal, immune system, and BRCA mutations, androgen receptor expressions, and cancer cell properties.

The market is expected to exponentially increase with further developments in genomic technologies and computer approaches. Varying phases of clinical trials include a variety of microRNA therapeutic products which can potentially indicate Hepatitis C virus, vascular disease, peripheral artery disease, cardiometabolic disease and various types of cancer. Miravirsen, for example, is the first therapeutic miRNA to enter the market. The drug is in the USA, Slovakia, Romania, Poland, Germany and the Netherlands for Phase II clinical trials. In preclinical trials using these molecules, high potential demonstrated by therapeutics is anticipated to promote investment in R&D in years to come.

Cancer segment to dominate the global microRNA market in terms of application

As such RNAs are ideal applicants as noninvasive biomarkers the cancer segment has dominated the miRNA market in revenue. It is an ideal marker for the sectioning and presence by microRNAs from cells in biofluids. These molecules are additionally classified by their ability to detect types of cancer at different nodes. In the detection of breast and prostate cancer for example, miR-27b, let-7i, and miR-181b.

In different conditions of health, research instruments are used to detect, quantify and analyze miRNAs in function. Increases researchers ‘ interest in these molecules to understand the cause and mechanism of complicated metabolic and neurological disease, such as cancer, Parkinson disease and Alzheimer’s disease, identifies the significant role of molecules in translational and transcriptional Gen expression.

Strong technical support led the North America region to dominate the global market

Due to strong technical support and enhanced research infrastructure in proteomics, genomics, modern diagnostics research as well as oncology, North America is expected to dominate this market over the forecast period. The fund approval, through the European Union, is expected to contribute to market growth in Europe for initiatives such as the EpimiRNA consortium.

In addition, rapid progress is expected to foster Asia Pacific growth in genomic studies and increasing use of advanced technologies. The development of products, comprising sets and packaging, is supplemented in the region by local players in China and Japan, majorly TaKaRa Bio. Due to reproducibility and reliability issues, the design, approval and launch of products for hospital and clinical use are faced with various challenges. The complexity and low stability of miRNAs further increase the development difficulties. The spiraling demand for precision medicine and early diagnostic tests combined with the capacity for these molecules to meet this demand has, however, encouraged the search for new approaches and strategies.

Major players profiled in the global market report include Agilent Technologies; Thermofisher Scientific (Life Technologies); QIAGEN (Exiqon); Merck KGaA;  as well as NanoString Technologies, Inc. among others.

Report Description

MicroRNA is a small RNA non coding which plays a major role in the use of plants and animals in degradation or repression of certain mRNAs. The growth of the market will be driven by an increasing number of biotechnology and pharmaceutical companies engaged in R & D activities, such as molecular diagnoses and therapeutics. A great deal of opportunities are anticipated in the near future to further expand fuel in virology, cardiovascular, endocrinology, genetic diseases and plant science. Recent innovations and various applications are expected to contribute over the forecast period to market growth for microRNA. The technology is used for the diagnosis and treatment of cancer as a biomarker. More investments in R&D initiatives are also expected to fuelled demand for new diagnostic tests and therapeutics. Increased RNAi therapy target selectivity and specificity, along with the adoption of models for virtual drug development, enable enterprises to minimize research and production costs.

It is expected that the shift from platform technologies to applications will well bode for market expansion. The development of drugs or biologics by virtual platforms for medication development offers important advantages over traditional models, such as reducing risks and overhead costs linked to conventional technologies. MirNAs play an important role in different biological processes, such as developmental time-control, cell proliferation, apoptosis, maintenance of stem cells, differentiation, pathways to signaling and pathogenesis, for example carcinogenesis. This factor is expected to increase market growth during the forecast period. The provision of large-scale public and private funding is one of the main factors contributing to market growth. Government investment and growing developments in technology are expected to drive further growth. It is hoped that a high disease prevalence will promote R&D in different disease classes for pharmaceutical and biotechnological companies. Increasing cardiovascular and cancer occurrences are expected to lead to a steady market rate. In 2012, around 14 million cases of cancer were recorded, according to the WHO, and in future years the number is expected to rise at an alarming rate. On the other hand, the main constraints on the global market are expected to be stringent regulations and high investment costs. High costs for the detection of miRNA and extensive and time-consuming test methods, therefore increase the overall value of the research. High failure rates and the lack of qualified professionals with excellent experience in the industry could hamper the growth of the market. Increasing cooperation and fusions between biotechnology companies and government research agencies will, however, have a positive impact on market growth.

The global microRNA market can be segmented on the basis of application, end user and geography. On the basis of application, the global microRNA market is classified into clinical diagnostics and research. Considering end user, the global microRNA market can be bifurcated into research and academic institutes, contract research organizations, biopharmaceutical companies and diagnostic centers. Based on geography, the global microRNA market is bifurcated into North America, Latin America, Europe, Middle East & Africa and Asia-Pacific.

Some of the major players operating in the global microRNA market include Affymetrix; Alnylam Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Santaris Pharma; Biogen Idec, Inc., Exiqon; Pfizer Inc., CBC Biomarker Center GmbH, Eli Lilly and Co., F. Hoffman-La Roche, GlaxoSmithKline, Novartis AG and Merck & Co. among others.

Table of Content

Chapter 1. Executive Summary

Chapter 2. Market Introduction

Chapter 3. Global MicroRNA Market – Analysis and Revenue Forecast 2018-2025 – Key Industry Dynamics

  • 3.1. Key Market Drivers
  • 3.2. Key Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Future Trends
  • 3.5. Impact Analysis of Drivers and Restraints

Chapter 4. Global MicroRNA Market – Analysis and Revenue Forecast 2018-2025

Chapter 5. Global MicroRNA Market – Analysis and Revenue Forecast 2018-2025 – By Application

  • 5.1. Clinical Diagnostics
  • 5.2. Research

Chapter 6. Global MicroRNA Market – Analysis and Revenue Forecast 2018-2025 – By End Use

  • 6.1. Research and academic institutes
  • 6.2. Contract research organizations
  • 6.3. Biopharmaceutical companies
  • 6.4. Diagnostic centers

Chapter 7. Global MicroRNA Market – Analysis and Revenue Forecast 2018-2025 – By Region

  • 7.1. North America
  • 7.2. Europe
  • 7.3. Asia-Pacific
  • 7.4. Latin America
  • 7.5. Middle East & Africa

Chapter 8. North America MicroRNA Market – Analysis and Revenue Forecast 2018-2025

  • 8.1. North America MicroRNA Market – By Application
    • 8.1.1. Clinical Diagnostics
    • 8.1.2. Research
  • 8.2. North America MicroRNA Market – By End Use
    • 8.2.1. Research and academic institutes
    • 8.2.2. Contract research organizations
    • 8.2.3. Biopharmaceutical companies
    • 8.2.4. Diagnostic centers
  • 8.3. North America MicroRNA Market – By Country
    • 8.3.1. U.S.
    • 8.3.2. Canada

Chapter 9. Europe MicroRNA Market – Analysis and Revenue Forecast 2018-2025

  • 9.1. Europe MicroRNA Market – By Application
    • 9.1.1. Clinical Diagnostics
    • 9.1.2. Research
  • 9.2. Europe MicroRNA Market – By End Use
    • 9.2.1. Research and academic institutes
    • 9.2.2. Contract research organizations
    • 9.2.3. Biopharmaceutical companies
    • 9.2.4. Diagnostic centers
  • 9.3. Europe MicroRNA Market – By Country
    • 9.3.1. Germany
    • 9.3.2. France
    • 9.3.3. UK
    • 9.3.4. Spain
    • 9.3.5. Italy
    • 9.3.6. Rest of Europe

Chapter 10. Asia-Pacific MicroRNA Market – Analysis and Revenue Forecast 2018-2025

  • 10.1. Asia-Pacific MicroRNA Market – By Application
    • 10.1.1. Clinical Diagnostics
    • 10.1.2. Research
  • 10.2. Asia-Pacific MicroRNA Market – By End Use
    • 10.2.1. Research and academic institutes
    • 10.2.2. Contract research organizations
    • 10.2.3. Biopharmaceutical companies
    • 10.2.4. Diagnostic centers
  • 10.3. Asia-Pacific MicroRNA Market – By Country
    • 10.3.1. China
    • 10.3.2. India
    • 10.3.3. Japan
    • 10.3.4. South Korea
    • 10.3.5. Rest of Asia-Pacific

Chapter 11. Latin America MicroRNA Market – Analysis and Revenue Forecast 2018-2025

  • 11.1. Latin America MicroRNA Market – By Application
    • 11.1.1. Clinical Diagnostics
    • 11.1.2. Research
  • 11.2. Latin America MicroRNA Market – By End Use
    • 11.2.1. Research and academic institutes
    • 11.2.2. Contract research organizations
    • 11.2.3. Biopharmaceutical companies
    • 11.2.4. Diagnostic centers
  • 11.3. Latin America MicroRNA Market – By Country
    • 11.3.1. Brazil
    • 11.3.2. Mexico
    • 11.3.3. Rest of Latin America

Chapter 12. Middle East & Africa MicroRNA Market – Analysis and Revenue Forecast 2018-2025

  • 12.1. MEA MicroRNA Market – By Application
    • 12.1.1. Clinical Diagnostics
    • 12.1.2. Research
  • 12.2. MEA MicroRNA Market – By End Use
    • 12.2.1. Research and academic institutes
    • 12.2.2. Contract research organizations
    • 12.2.3. Biopharmaceutical companies
    • 12.2.4. Diagnostic centers
  • 12.3. Middle East & Africa MicroRNA Market – By Country
    • 12.3.1. UAE
    • 12.3.2. Saudi Arabia
    • 12.3.3. Turkey
    • 12.3.4. Rest of Middle East & Africa

Chapter 13. Competitive Analysis

  • 13.1.1. Competition Dashboard
  • 13.1.2. Company Profiles
    • 13.1.2.1. Biogen Idec Inc.
    • 13.1.2.2. Pfizer Inc.
    • 13.1.2.3. Novartis AG
    • 13.1.2.4. Affymetrix
    • 13.1.2.5. Alnylam Pharmaceuticals
    • 13.1.2.6. AstraZeneca Pharmaceuticals LP
    • 13.1.2.7. Santaris Pharma
    • 13.1.2.8. CBC Biomarker Center GmbH
    • 13.1.2.9. Eli Lilly and Co.
    • 13.1.2.10. F. Hoffman-La Roche
    • 13.1.2.11. GlaxoSmithKline
    • 13.1.2.12. Merck & Co.
Report Methodology
Report Customization
Report Sample
Consult the Analyst